IBBR Institute for Bioscience and Biotechnology Research

ibbr.umd.edu

IBBR is a University System of Maryland joint research enterprise among the University of Maryland College Park, the University of Maryland Baltimore, and the National Institute of Standards and Technology. With a long-standing scientific focus on structure-function relationships of biomolecules, genetic systems, and applications, e.g., vaccines, therapeutics, drug delivery technologies, and biomanufacturing, IBBR’s mission is to leverage its unique capabilities and infrastructure to marshal innovative technologies and expertise across its partnering institutions, to foster integrated, cross-disciplinary team approaches to scientific research and education, and to pursue translational programs and projects aimed at advancing innovations to commercialization in real world applications. The Institute also serves to expand the economic base of science and technology in the state of Maryland and at the national level.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

FLUENT BIOSCIENCES AND NANOCELLECT ANNOUNCE JOINT COLLABORATION TO IMPROVE RESOLUTION OF SINGLE-CELL RNA SEQUENCING ANALYSIS OF RARE CELL POPULATIONS

Fluent BioSciences | June 18, 2022

news image

Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, and NanoCellect Biomedical, Inc., a leader in the development and manufacturing of innovative and affordable solutions for cell sorting, jointly announced a collaboration to improve resolution and efficiency of single-cell RNA sequencing (scRNA-seq) analysis of rare cell populations. Single-cell researchers are increasingly requiring scalable, flexible and ...

Read More

MedTech

BIOAGE PARTNERS WITH AGE LABS TO DECIPHER HEALTHY LONGEVITY USING SAMPLES AND DATA FROM A PREEMINENT NORTHERN EUROPEAN BIOBANK

BioAge Labs, Inc. | August 24, 2022

news image

BioAge Labs, Inc. a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it has initiated a partnership agreement with Age Labs AS a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records from the Nord-Trøndelag Health Study biobank collected from more than 100,000...

Read More

Industrial Impact, Diagnostics

VAXXINITY ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF VXX-401, INVESTIGATIONAL ANTI-PCSK9 VACCINE TO TREAT HYPERCHOLESTEROLEMIA

Vaxxinity, Inc. | March 21, 2023

news image

Vaxxinity, Inc. a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor contributing to heart disease, by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9). Heart disease remains the leading cau...

Read More

AI

WHITELAB GENOMICS AND THE ACCELERATOR FOR TECHNOLOGICAL RESEARCH IN GENOMIC THERAPIES COLLABORATE ON AI FOR GENE THERAPY BIOPRODUCTION

WhiteLab Genomics | June 01, 2021

news image

As part of this collaboration, teams from the Accelerator for Technological Research in Genomic Therapies (ART-TG, Inserm US35) and WhiteLab Genomics will use the WhiteLab Genomics CatalystTM platform to generate a database specific to the bioproduction of lentiviral vectors, which will be used to identify the parameters allowing for a significant increase in vector quality as well as their production yields, and to reduce the production costs. Cell and gene therapy is a new biome...

Read More
news image

Medical

FLUENT BIOSCIENCES AND NANOCELLECT ANNOUNCE JOINT COLLABORATION TO IMPROVE RESOLUTION OF SINGLE-CELL RNA SEQUENCING ANALYSIS OF RARE CELL POPULATIONS

Fluent BioSciences | June 18, 2022

Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, and NanoCellect Biomedical, Inc., a leader in the development and manufacturing of innovative and affordable solutions for cell sorting, jointly announced a collaboration to improve resolution and efficiency of single-cell RNA sequencing (scRNA-seq) analysis of rare cell populations. Single-cell researchers are increasingly requiring scalable, flexible and ...

Read More
news image

MedTech

BIOAGE PARTNERS WITH AGE LABS TO DECIPHER HEALTHY LONGEVITY USING SAMPLES AND DATA FROM A PREEMINENT NORTHERN EUROPEAN BIOBANK

BioAge Labs, Inc. | August 24, 2022

BioAge Labs, Inc. a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it has initiated a partnership agreement with Age Labs AS a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records from the Nord-Trøndelag Health Study biobank collected from more than 100,000...

Read More
news image

Industrial Impact, Diagnostics

VAXXINITY ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF VXX-401, INVESTIGATIONAL ANTI-PCSK9 VACCINE TO TREAT HYPERCHOLESTEROLEMIA

Vaxxinity, Inc. | March 21, 2023

Vaxxinity, Inc. a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor contributing to heart disease, by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9). Heart disease remains the leading cau...

Read More
news image

AI

WHITELAB GENOMICS AND THE ACCELERATOR FOR TECHNOLOGICAL RESEARCH IN GENOMIC THERAPIES COLLABORATE ON AI FOR GENE THERAPY BIOPRODUCTION

WhiteLab Genomics | June 01, 2021

As part of this collaboration, teams from the Accelerator for Technological Research in Genomic Therapies (ART-TG, Inserm US35) and WhiteLab Genomics will use the WhiteLab Genomics CatalystTM platform to generate a database specific to the bioproduction of lentiviral vectors, which will be used to identify the parameters allowing for a significant increase in vector quality as well as their production yields, and to reduce the production costs. Cell and gene therapy is a new biome...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us